6 January 2025
Graham Shelton, our Founder and Chairman, stepped down at the end of December 2024. We were proud to mark his retirement at our Oxford party, and present him with a book of memories from current and former colleagues and clients from around the world.
Three tips for making your communications more omnichannel We conducted a survey of the Medical Affairs community at the MAPS 2024 Americas event and discovered a common theme. We found that many Medical Affairs professionals want to think about content communication in a more omnichannel way. Here are three practical tips to help to create…
Oxford PharmaGenesis welcomes Christopher Rains on board as our first Non-Executive Director Oxford PharmaGenesis is proud to announce the appointment of Christopher Rains as our first Non-Executive Director, strengthening the Board with over 30 years of experience in the pharmaceutical industry. A former executive at Takeda, Shire and AstraZeneca, Chris brings unparalleled knowledge and expertise…
For the fourth year running, media brand Medical Marketing and Media (MM+M) has listed Oxford PharmaGenesis in its Agency 100 report – the annual definitive ‘who’s who’ ranking of the healthcare sector’s top marketing firms in North America. A key indicator of the sector’s health, the hotly anticipated report spotlights the most accomplished players in…
Author: Kate Haynes – Communications Director at Oxford PharmaGenesis At Oxford PharmaGenesis, we appreciate the importance of impact and the need for our clients to achieve it. It was therefore serendipitous that the theme of the 2024 Medical Affairs Professional Society (MAPS) European congress was ‘impact’ and how this notoriously elusive goal can be attained…
Navigating the narrative: insights from the 20th Annual Meeting of the International Society for Medical Publication Professionals (ISMPP) As medical publication professionals, we are natural storytellers, expertly crafting intricate narratives that transform data into engaging stories and simplifying complex medical concepts for a broader audience. The essence of this skill was a recurring theme at…
HEOR and market access are evolving, with changes in HTA, acceleration in the use of RWE and increased reactions to cost-containment measures. We are contributing to conversations about how these changes affect value demonstration strategies. At Oxford PharmaGenesis, we are experts in advising on payer strategy, developing payer evidence and supporting payer evaluation. We understand differences in payer evidence needs, and we know how to create compelling value stories for our clients that achieve powerful results.
